Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 6
Submit an article Journal homepage
48
Views
13
CrossRef citations to date
0
Altmetric
Primary Research

Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries

Anna Bucsics Hauptverband der Österreichischen Sozialversicherungsträger, Kundmanngasse 21, A-1031 Wien, Austria
,
Brian Godman Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden. [email protected]; Mario Negri Institute for Pharmacological Research, Via Giuseppe La Masa 19, 20156 Milan, Italy; Prescribing Research Group, University of Liverpool Management School, Chatham Street, Liverpool, UK; Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden. [email protected]; Mario Negri Institute for Pharmacological Research, Via Giuseppe La Masa 19, 20156 Milan, Italy; Prescribing Research Group, University of Liverpool Management School, Chatham Street, Liverpool, UK
,
Thomas Burkhardt Hauptverband der Österreichischen Sozialversicherungsträger, Kundmanngasse 21, A-1031 Wien, Austria
,
Manuela Schmitzer Hauptverband der Österreichischen Sozialversicherungsträger, Kundmanngasse 21, A-1031 Wien, Austria
&
Rickard E Malmström Department of Medicine, Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden
Pages 809-819 | Published online: 09 Jan 2014

References

  • Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 8(4), 357–371 (2008).
  • Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl. Health Econ. Health Policy 8(1), 7–24 (2010).
  • Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 26(7), 537–550 (2008).
  • Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9(1), 65–83 (2009).
  • Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373(9659), 240–249 (2009).
  • Garattini S, Bertele’ V, Godman B, Haycox A, Wettermark B, Gustafsson LL; Piperska Group. Enhancing the rational use of new medicines across European health care systems. Eur. J. Clin. Pharmacol. 64(12), 1137–1138 (2008).
  • Godman B, Shrank W, Wettermark B, Andersen M, Bishop I et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470–2494 (2010).
  • Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(6), 707–722 (2010).
  • Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Frontiers Pharmacol. 1(141), 1–16 (2011).
  • Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91–98 (2008).
  • Godman B, Wettermark B, Bishop I, et al. European payer initiatives to reduce prescribing costs through use of generics. GABI 1, 22–27 (2012).
  • Voncina L, Strizrep T, Godman B et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 469–479 (2011).
  • Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev. Pharmacoecon. Outcomes Res. 11(3), 343–349 (2011).
  • McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(1), 73–85 (2010).
  • Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 125–130 (2012).
  • Dylst P, Vulto A, Simoens S. The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev. Pharmacoecon. Outcomes Res. 11(6), 729–737 (2011).
  • Simoens S. A review of generic medicine pricing in Europe. GaBI 1, 8–12 (2012).
  • Godman B, Abuelkhair M, Vitry A, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI 1(2), 21–35 (2012).
  • Godman B, Malmstrom RE, Bennie M et al. Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency? Rev. Health Care 3, 5–16 (2012).
  • Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9(5), 475–484 (2009).
  • Godman B, Bucsics A, Burkhardt T, Schmitzer M, Wettermark B, Wieninger P. Initiatives to enhance renin–angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Rev. Pharmacoecon. Outcomes Res. 10(2), 199–207 (2010).
  • Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev. Pharmacoecon. Outcomes Res. 11(1), 121–129 (2011).
  • Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9(6), 569–581 (2009).
  • Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost–effectiveness of antihypertensive treatment. Health Policy 94(3), 221–229 (2010).
  • Gustafsson LL, Wettermark B, Godman B et al.; Regional Drug Expert Consortium. The ‘wise list’– a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108(4), 224–233 (2011).
  • Godman B, Paterson K, Malmstrom R et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev. Pharmacoecon. Outcomes Res. 12(4), 439–441(2012).
  • Markovic-Pekovic V, Ranko Škrbić R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directionse. Expert Rev. Pharmacoecon. Outcomes Res. 12(5), 661–671 (2012).
  • Fletcher AE, Palmer AJ, Bulpitt CJ. Cough with angiotensin converting enzyme inhibitors: how much of a problem? J. Hypertens. Suppl. 12(2), S43–S47 (1994).
  • Frisk P, Mellgren TO, Hedberg N, Berlin A, Granath F, Wettermark B. Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines. Eur. J. Clin. Pharmacol. 64(12), 1223–1229 (2008).
  • Elliot H. Focus on the ONTARGET results. J. Hypertens. 27, S8–S10 (2009).
  • McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332(7551), 1177–1181 (2006).
  • Moon J, Flett A, Godman B, Grosso A, Wierzbicki A. Getting better value from the NHS drug budget. BMJ 342, 30–32 (2011).
  • Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst. Rev. 4, CD003822 (2008).
  • Nixon RM, Müller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract. 63(5), 766–775 (2009).
  • Svanström H, Pasternak B, Hviid A. Association of treatment with losartan vs candesartan and mortality among patients with heart failure. JAMA 307(14), 1506–1512 (2012).
  • Krum H. Optimising management of chronic heart failure. Lancet 374(9704), 1808–1809 (2009).
  • Konstam MA, Neaton JD, Dickstein K et al.; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374(9704), 1840–1848 (2009).
  • Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62(3), 480–484 (2008).
  • Grimshaw J, Campbell M, Eccles M, Steen N. Experimental and quasi-experimental designs for evaluating guideline implementation strategies. Fam. Pract. 17(Suppl. 1), S11–S16 (2000).
  • Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J. Clin. Pharm. Ther. 27(4), 299–309 (2002).
  • Vlahovic-Palcevski V, Gantumur M, Radosevic N, Palcevski G, Vander Stichele R. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci. 32(2), 125–129 (2010).
  • Spiegel W, Mlczoch-Czerny MT, Jens R, Dowrick C. Quality circles for pharmacotherapy to modify general practitioners’ prescribing behaviour for generic drugs. J. Eval. Clin. Pract. 18(4), 828–834 (2012).
  • Pettersson B, Hoffmann M, Wändell P, Levin LÅ. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 104(1), 84–91 (2012).
  • Godman B, Bennie M, Baumgärtel C, Sović Brkičić L et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia: Health Economics & Therapeutic Pathways (2012) (In Press).
  • Sakshaug S, Furu K, Karlstad Ø, Rønning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br. J. Clin. Pharmacol. 64(4), 476–481 (2007).
  • Martikainen JE, Saastamoinen LK, Korhonen MJ, Enlund H, Helin-Salmivaara A. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med. Care 48(9), 761–766 (2010).
  • Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 137–147 (2009).
  • Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ 317(7156), 465–468 (1998).
  • Barton S. Using clinical evidence. BMJ 322(7285), 503–504 (2001).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.